Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Edgewise Therapeutics (EWTX) Accumulated Depreciation & Amortization (2020 - 2026)

Edgewise Therapeutics has reported Accumulated Depreciation & Amortization over the past 7 years, most recently at $7.3 million for Q1 2026.

  • Quarterly results put Accumulated Depreciation & Amortization at $7.3 million for Q1 2026, up 40.55% from a year ago — trailing twelve months through Mar 2026 was $7.3 million (up 40.55% YoY), and the annual figure for FY2025 was $6.8 million, up 44.48%.
  • Accumulated Depreciation & Amortization reached $7.3 million in Q1 2026 per EWTX's latest filing, up from $6.8 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $7.3 million in Q1 2026 and bottomed at $785000.0 in Q1 2022.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $3.1 million (2024), compared with a mean of $3.4 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization skyrocketed 145.63% in 2023 before it soared 40.55% in 2026.
  • Over 5 years, Accumulated Depreciation & Amortization stood at $1.1 million in 2022, then surged by 145.63% to $2.6 million in 2023, then skyrocketed by 79.09% to $4.7 million in 2024, then skyrocketed by 44.48% to $6.8 million in 2025, then grew by 7.93% to $7.3 million in 2026.
  • Business Quant data shows Accumulated Depreciation & Amortization for EWTX at $7.3 million in Q1 2026, $6.8 million in Q4 2025, and $6.2 million in Q3 2025.